A protein treatment to protect babies' hearts during heart surgery
Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass
A protein medicine called OMX aims to deliver oxygen to protect the hearts and organs of newborns and infants during cardiopulmonary bypass surgery.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Omniox, INC. NIH-funded |
| Lab location | 1 site (San Francisco, UNITED STATES) |
| Project ID | NIH-11167638 on NIH RePORTER |
What this research studies
This project is developing OMX, an oxygen-carrying protein that would be given around the time of cardiopulmonary bypass to reduce oxygen loss to the heart and other organs in newborns and young infants. The work builds on earlier safety and preliminary data and includes laboratory and animal studies with clinical collaborators at UCSF. The goal is to refine the product and the dosing strategy so it can move toward use in babies having surgery for congenital heart defects. If development milestones are met, the next steps would be clinical testing at specialized pediatric heart centers.
Who could benefit from this research
Good fit: Newborns and infants undergoing cardiopulmonary bypass for surgical repair of congenital heart defects would be the intended candidates.
Not a fit: Children and adults not having cardiopulmonary bypass or babies whose problems are not caused by surgery-related oxygen deprivation would not be expected to benefit or be eligible.
Why it matters
Potential benefit: If successful, OMX could lower organ damage and post-operative complications and improve short- and long-term outcomes after infant heart surgery.
How similar studies have performed: Using oxygen-carrying agents during surgery is a relatively new approach in newborn cardiac care and prior oxygen carrier products have had mixed results, so this application is promising but not yet proven in patients.
Where this research is happening
San Francisco, UNITED STATES
- Omniox, INC. — San Francisco, United States (Active)
Researchers
- Principal investigator: Winger, Jonathan a — Omniox, INC.
- Study coordinator: Winger, Jonathan a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.